Literature DB >> 2007582

Activation of phospholipase A2 by adriamycin in vitro. Role of drug-lipid interactions.

P Mustonen1, P K Kinnunen.   

Abstract

To probe adriamycin-phospholipid interactions, the effects of this cytotoxin on the hydrolysis of a pyrene-labeled acidic alkyl-acyl phospholipid analog 1-octa-cosanyl-2-(6-pyren-1-yl)hexanoyl-sn-glycero-3-phos p hatidylmethanol (C28-O-PHPM) by porcine pancreatic phospholipase A2 (PLA2) were studied. In the absence of added Ca2+ adriamycin caused a 3-4-fold activation of hydrolysis of this pyrenelipid whereas an inhibition of action of PLA2 on the corresponding phosphatidylcholine derivative C28-O-PHPC was observed. Under similar conditions adriamycin also enhanced the rate of hydrolysis of the pyrene-labeled diacyl lipid 1-palmitoyl-2-(pyren-1-yl)hexanoyl-sn-glycero-3-phosphatidylgly cer ol and inhibited the hydrolysis of PLA2 on the phosphatidylcholine derivative. Increasing calcium concentrations abolished the activating and most of the inhibitory effects of adriamycin with the above phospholipid substrates. Quenching of pyrene excimer fluorescence by adriamycin revealed efficient binding of the drug to acidic lipids. Addition of 1 mM calcium reduced fluorescence quenching by adriamycin maximally by approximately 90%. In comparison, quenching by adriamycin of pyrene-labeled phosphatidylcholine was much weaker and calcium had only an insignificant effect. Monolayer experiments at an air/water interface showed a rapid and surface pressure-dependent penetration of the drug into a film of C28-O-PHPM. Increase in surface pressure was reversed by 80% by the inclusion of 1 mM Ca2+ into the subphase. Penetration of adriamycin into a monolayer of C28-O-PHPC was much weaker. In agreement with earlier studies two types of binding of adriamycin to C28-O-PHPM are proposed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007582

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity.

Authors:  G Minotti; C Mancuso; A Frustaci; A Mordente; S A Santini; A M Calafiore; G Liberi; N Gentiloni
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Measurement of the binding of DNA to liposomes by resonance energy transfer.

Authors:  A Köiv; P K Kinnunen
Journal:  J Fluoresc       Date:  1994-12       Impact factor: 2.217

3.  Characteristics of the binding of tacrine to acidic phospholipids.

Authors:  J Y Lehtonen; M Rytömaa; P K Kinnunen
Journal:  Biophys J       Date:  1996-05       Impact factor: 4.033

4.  Modulation of the activity of secretory phospholipase A2 by antimicrobial peptides.

Authors:  Hongxia Zhao; Paavo K J Kinnunen
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

5.  Interactions of adriamycin, cytochrome c, and serum albumin with lipid monolayers containing poly(ethylene glycol)-ceramide.

Authors:  Hongxia Zhao; Patricia M Dubielecka; Tim Söderlund; Paavo K J Kinnunen
Journal:  Biophys J       Date:  2002-08       Impact factor: 4.033

6.  Phospholipase A2 as a mechanosensor.

Authors:  J Y Lehtonen; P K Kinnunen
Journal:  Biophys J       Date:  1995-05       Impact factor: 4.033

7.  Binding of adriamycin to liposomes as a probe for membrane lateral organization.

Authors:  T Söderlund; A Jutila; P K Kinnunen
Journal:  Biophys J       Date:  1999-02       Impact factor: 4.033

8.  Changes in the lipid dynamics of liposomal membranes induced by poly(ethylene glycol): free volume alterations revealed by inter- and intramolecular excimer-forming phospholipid analogs.

Authors:  J Y Lehtonen; P K Kinnunen
Journal:  Biophys J       Date:  1994-06       Impact factor: 4.033

9.  Oxidized phospholipids as potential novel drug targets.

Authors:  Juha-Pekka Mattila; Karen Sabatini; Paavo K J Kinnunen
Journal:  Biophys J       Date:  2007-06-29       Impact factor: 4.033

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.